What Skyepharma- Fully Integrated Cdmo does

Skyepharma Production S.A.S. is a France-based contract development and manufacturing organization (CDMO) founded in 1999 and headquartered in Saint-Quentin-Fallavier, specializing in complex oral solid dosage forms (OSD) for the global pharmaceutical industry. Its service portfolio spans formulation development, clinical and commercial manufacturing, and packaging, supported by proprietary drug delivery platforms including Geomatrix® (multi-layer modified-release matrix), Geoclock®, Soctec® (amorphous solid dispersion for bioavailability enhancement), and the newly filed MucoTabS mucoadhesive/pH-sensitive tablet technology. Manufacturing capacity is designed for high-containment HPAPI handling, and the company has expanded into adjacent capabilities through the Skyehub bioproduction unit, established with MaaT Pharma as one of the first European cGMP facilities dedicated to live biotherapeutic (microbiome) manufacturing. Operations are inspected and approved by the FDA, ANSM, and ANVISA, enabling commercial product supply to more than 160 countries.

The company serves roughly 20 disclosed international pharmaceutical clients, spanning large-cap pharma names such as Bayer, Teva, Chiesi, and Dr Reddys alongside specialty and mid-stage biotechs including MaaT Pharma, Biophytis, Calliditas, Advanz, and Azurity. Revenue is generated on a project-based, quote-driven model tied to development and commercial manufacturing contracts. Disclosed revenue reached €29 million in 2024, with +33% cumulative growth over the prior three years; the workforce expanded to 217 employees, approximately one-quarter of whom hold PhDs. In November 2025, the company was acquired 100% by entrepreneurs Bertrand Simon and Hervé Letoublon via their holding company Oleron Pharma, with Sébastien Mas appointed CEO, marking a transition to private sponsor ownership following an earlier 2016 management buyout of the plant.

Name

Skyepharma- Fully Integrated Cdmo

Legal name

Skyepharma Production S.A.S.

Website

https://skyepharma.com

Company type

Private

Founded year

1999

Operating status

Operating

Short description

Skyepharma is a French CDMO founded in 1999, specializing in complex oral solid dosage forms — formulation development, clinical/commercial manufacturing, and packaging — for global pharma and biotech clients, with proprietary delivery platforms and regulatory approvals spanning 160+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Contract pharmaceutical manufacturing
• Oral solid dosage forms
• Controlled release technology
• HPAPI containment manufacturing
• Pharmaceutical development services

Headquarters

HQ city

Saint-quentin-fallavier

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Services: Contract Development and Manufacturing Organization providing integrated pharmaceutical services from early-stage development through commercial manufacturing and packaging of oral solid dosage forms. Revenue generated through project-based contracts with pharmaceutical companies for R&D, manufacturing, and packaging services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Skyepharma is a fully integrated French CDMO (Contract Development and Manufacturing Organization) specializing in complex oral solid dosage forms, providing end-to-end pharmaceutical services spanning preformulation, formulation development, analytical method development, cGMP manufacturing, and packaging for oral solid dosage forms. The company operates a single-site integrated platform that eliminates technology transfers between development and manufacturing, supporting clients from early Phase I clinical supply through commercial production and packaging.

Product overview

Skyepharma is a fully integrated French CDMO (Contract Development and Manufacturing Organization) specializing in complex oral solid dosage forms. The company operates a unified platform combining pharmaceutical development, cGMP manufacturing, and packaging services. The core product portfolio includes three proprietary controlled-release technology platforms: Geomatrix® (multi-layer tablet system), Geoclock® (press-coated timed release), and Soctec® (gastro-retentive capsule), alongside innovation programs such as MucoTabS (mucoadhesive GI-targeting tablets), Nanomics/Nanofact (bioavailability enhancement), and GeoColon (colonic delivery). The Skyehub bioproduction brand offers built-on-demand GMP facilities for biotech companies. Manufacturing capabilities span standard oral solid forms as well as specialized areas including HPAPI handling (OEB 4/5+), non-sexual hormones, and orphan drugs. The FlexiPack Line provides specialized small-batch packaging for rare disease therapies. Services are complemented by regulatory support, analytical development, and project management under a single organizational umbrella.

Differentiator

Problem solved

Functional benefit

Brands

• Skyehub: Unique and tailor-made biotechnology support offer providing built-on-demand GMP facility for bioproduction companies.

Products and services

• Pharmaceutical Development Services Full-service pharmaceutical development including preformulation, formulation development, analytical method development, and Quality by Design (QbD) approach. Addresses complex formulation challenges for oral solid dosage forms for pharmaceutical and biotech clients.
• Pharmaceutical Manufacturing Services cGMP manufacturing of oral solid dosage forms including tablets, capsules, granules/pellets, and film coating. Offers flexible batch sizes from clinical supply to commercial production, including HPAPI handling up to OEB 4/5+.
• Pharmaceutical Packaging Services Customized packaging solutions for oral solid dosage forms including bottles, blisters, and stick-packs. Includes full serialization and aggregation capabilities.
• Geomatrix® Controlled Release Platform Proprietary multi-layer controlled release tablet system enabling customized release profiles for oral solid dosage forms. Allows independent control of multiple active pharmaceutical ingredients within a single tablet for pharmaceutical and biotech clients.
• Geoclock® Press-Coated Timed Release Platform Proprietary press-coated tablet technology enabling timed and targeted release, including colonic delivery. Controls lag-time from 1 to 10 hours through modulation of compression pressure, layer thickness, and shell geometry.
• Soctec® Gastro-Retentive Capsule System Proprietary gastro-retentive capsule system designed to increase residence time in the stomach and improve API absorption in the upper GI tract, as part of the modified release technology portfolio.
• MucoTabS Targeted GI Delivery Platform Proprietary mucoadhesive and pH-sensitive tablet technology platform capable of targeting specific regions of the gastrointestinal tract (stomach, small intestine, colon). Combines mucoadhesive properties with pH-responsive behavior for precise, prolonged, and targeted drug delivery.
• Skyehub Bioproduction Services Built-on-demand GMP bioproduction facility offering tailor-made solutions for biotechnology companies. Provides pharmaceutical quality system, industrial support, and human/IT resources to support projects from clinical to industrial stages, including more than 1600m² dedicated to Microbiome Ecosystem Therapies.
• Buccal Permeability Platform In vitro buccal permeability screening platform using Franz diffusion cells and PermeaPad biomimetic membrane. Enables rapid API permeation assessment during preformulation studies for pharmaceutical and biotech clients. Supports small molecules and peptides with minimal API consumption.
• FlexiPack Line Packaging Service Semi-automatic packaging line dedicated to small-batch orphan drug products and clinical trial materials. Features right-sized batches, on-demand flexibility, and semi-automated precision packaging, eliminating high minimum order quantities.
• Regulatory Support Services Dedicated regulatory department supporting partners in obtaining and maintaining approvals from FDA, ANSM, ANVISA, and other regulatory authorities. Covers CMC dossiers for IND, CTA, and NDA/MAA filings.
• API Combination Technology Services Development and optimization of complex API combinations including fixed-dose combinations (FDCs). Leverages co-crystallization, encapsulation, and multi-layer tablet technology to achieve optimal API interaction and performance.
• Non-Sexual Hormones Manufacturing Contained cGMP area of approximately 1000 m² dedicated to non-sexual hormone production including thyroid hormones. Features dual-level containment with premise/equipment containment and employee PPE protection.
• HPAPI Manufacturing (OEB 4/5+) Segregated cGMP containment area for OEB 4/5+ molecules covering oncology, immuno-oncology, controlled substances, and NCE development and manufacturing. Equipped with stand-alone equipment and dedicated containment facilities.
• Press-Coated Tablet Development Services Research and development services for press-coated tablets enabling controlled lag-time and release kinetics. Studies geometric and process parameters (compression pressure, layer thickness, band thickness) to achieve lag-times from 1 to 10 hours.

Quantifiable outcome

• Products commercialized in over 160 countries through multi-regulatory approvals
• +3 more outcomes

Named customers12 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• MaaT PharmacoreStrategic or Co-development Partner · 1 February 2022Partnership established February 2022 to establish the first Skyehub building - the exclusive cGMP manufacturing facility for microbiome ecosystem therapies in France. More than 1600m² dedicated to Microbiome Ecosystem Therapies™. Skyehub provides built-on-demand GMP facility and tailor-made solutions supporting biotech projects from clinical to industrial stages.
• ENEAPHARMcoreStrategic or Co-development PartnerPartnership through Skyehub bioproduction platform to support treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Strengthens Skyepharma's positioning as a BIO CDMO and ambition in biotechnology sector development in Auvergne-Rhône-Alpes region and broader Europe.
• LAGEPP Laboratory (Université Claude Bernard Lyon 1)coreStrategic or Co-development PartnerAcademic-industry collaboration for MucoTabS innovation program. Research conducted under Pauline Tarlet's doctoral thesis supervised by Vanessa Bourgeaux (Head of Innovation) with faculty members including Stéphanie Briançon, Claire Bordes, and Sandrine Bourgeois. Aims to advance new generation of oral solid dosage forms with mucoadhesive and pH-sensitive properties.
• MedelpharmminorGTM or Marketing PartnerEvent partner for Skyepharma Scientific Symposium 2025 'Advances in Overcoming Oral Dosage Form Development Challenges'. Event focused on bioavailability, formulation and industrialization topics.
• GattefosseminorGTM or Marketing PartnerEvent partner for Skyepharma Scientific Symposium 2025. Contributing to oral dosage form development discussions around bioavailability and formulation.
• SeqensminorGTM or Marketing PartnerEvent partner for Skyepharma Scientific Symposium 2025.
• GEAminorGTM or Marketing PartnerEvent partner for Skyepharma Scientific Symposium 2025.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Others

• MaaT Pharma: French microbiome ecosystem therapy company whose partnership with Skyepharma anchors the Skyehub bioproduction facility. Comparable as a strategic partner and as a customer for the BIO-CDMO vertical rather than as a competitor.

Direct peers

• Hovione: Portugal-headquartered CDMO with integrated API and drug product capabilities including complex OSD and HPAPI handling. Closely comparable to Skyepharma in technology depth and target customer base.
• Recipharm: European CDMO with significant oral solid dosage form manufacturing capabilities serving similar pharma and biotech customers across development and commercial supply. Most directly comparable in geography and service scope to Skyepharma.
• CordenPharma: Full-service CDMO offering oral solid dosage forms, HPAPI, peptides, and injectables. Overlaps with Skyepharma on complex OSD and highly potent molecule manufacturing for pharma clients globally.
• Aenova: German-based CDMO with a strong oral solid dose portfolio and HPAPI capabilities. Competes head-to-head with Skyepharma for complex OSD and highly potent molecule projects across Europe.
• Delpharm: French-headquartered CDMO offering contract development and manufacturing of oral solid and sterile dosage forms. Direct competitor to Skyepharma in the French and European OSD CDMO market.
• Fareva: Privately held French pharmaceutical CDMO with broad manufacturing capabilities including oral solids, injectables, and cosmetics. Competes with Skyepharma for European pharma manufacturing contracts.

Broad incumbents

• Lonza: Global CDMO giant with broad small-molecule and biologics capabilities. While less focused on complex OSD specifically, competes for adjacent pharmaceutical development and HPAPI manufacturing work.
• Catalent: Global CDMO leader with comprehensive OSD, softgel, and biologics capabilities serving most major pharma sponsors. Operates at much greater scale than Skyepharma and competes for the same customers, but across a far wider portfolio.
• Thermo Fisher Scientific (Patheon): Global CDMO through its Patheon business offering integrated drug substance, drug product, and clinical packaging services including OSD. Competes with Skyepharma for large pharma commercial and development contracts at substantially greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCSj2WQGvNTrJr6vBqGo_rhA
• LinkedInlinkedin.com/company/skyepharma

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Skyepharma- Fully Integrated Cdmo